<div id="readability-page-1"><p>RBF Capital LLC bought a new stake in  Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor  bought 160,000 shares of the company's stock, valued at approximately $114,000. RBF Capital LLC owned 0.19% of Sutro Biopharma as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Sutro Biopharma</strong> alerts:</span></p></div><p>Several other institutional investors also recently added to or reduced their stakes in STRO. Catalyst Funds Management Pty Ltd acquired a new stake in shares of  Sutro Biopharma in the second quarter valued at approximately $27,000.  Savant Capital LLC acquired a new stake in  Sutro Biopharma during the 2nd quarter worth $37,000.  CWM LLC grew its position in  Sutro Biopharma by 73.2% during the 2nd quarter. CWM LLC now owns 56,657 shares of the company's stock worth $40,000 after purchasing an additional 23,941 shares during the last quarter.  Vanguard Personalized Indexing Management LLC increased its stake in  Sutro Biopharma by 174.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company's stock valued at $43,000 after purchasing an additional 38,561 shares during the period.  Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of  Sutro Biopharma in the second quarter valued at about $48,000. Institutional investors and hedge funds own  96.99% of the company's stock. </p><h2>Insider Buying and Selling</h2><p>In related news, Director Connie Matsui acquired 5,000 shares of the company's stock in a transaction that occurred on Wednesday, October 15th. The stock was purchased at an average price of $8.00 per share, for a total transaction of $40,000.00. Following the transaction, the director owned 5,000 shares in the company, valued at $40,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. In the last three months, insiders bought 11,175 shares of company stock worth $89,598. Company insiders own  3.60% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities research analysts have recently commented on STRO shares. Wall Street Zen cut Sutro Biopharma from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Sutro Biopharma in a research report on Monday, December 1st. Finally, Wedbush  reissued a &#34;neutral&#34; rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. One investment analyst  has rated the stock with a Buy rating, four have assigned  a Hold rating and two have assigned  a Sell rating to the stock. Based on data from MarketBeat.com, Sutro Biopharma presently has an average rating of &#34;Reduce&#34; and an average price target of $35.60.</p><p><b>Get Our Latest Stock Analysis on STRO</b></p><h2>Sutro Biopharma Stock Up 6.0%</h2><p>Shares of STRO stock opened at $9.00 on Thursday. The stock has a market cap of $76.59 million, a P/E ratio of -0.34 and a beta of 1.61. Sutro Biopharma, Inc. has a fifty-two week low of $5.23 and a fifty-two week high of $24.80. The business has a fifty day simple moving average of $9.25 and a 200-day simple moving average of $8.74. </p><p>Sutro Biopharma (NASDAQ:STRO - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.25). The company had revenue of $9.69 million for the quarter, compared to analyst estimates of $10.14 million. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%.  On average, sell-side analysts anticipate that  Sutro Biopharma, Inc. will post -2.92 earnings per share for the current year. </p><h2>About Sutro Biopharma</h2> (Free Report)<p>Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Sutro Biopharma</li><li>What is the Hang Seng index?  </li><li>GameStop Looks Broken: Here’s Why GME Could Crash in 2026</li><li>How to Invest in Blue Chip Stocks</li><li>Market Momentum: 3 Stocks Poised for Major Breakouts</li><li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li><li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li></ul><p><strong>Want to see what other hedge funds are holding STRO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RSTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RSTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sutro Biopharma Right Now?</h2><p>Before you consider Sutro Biopharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.</p><p>While Sutro Biopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

STRO

<p>RBF Capital LLC acquired a new stake in Sutro Biopharma, purchasing 160,000 shares valued at approximately $114,000. This move was part of several institutional investments in the company during the second quarter. Sutro Biopharma's stock has been rated as 'Reduce' by analysts, with a current price target of $35.60. The company, a clinical-stage oncology firm, reported a Q3 loss, missing analyst expectations. Institutional investors own 96.99% of the stock, while insiders hold 3.60%.</p>

RBF Capital LLC Purchases New Position in Sutro Biopharma, Inc. $STRO